The association between inhaled fenoterol and death from asthma has been investigated further by studying 112 asthma deaths (cases) during 1981-7 in patients aged 5-45 years who had been admitted to a major hospital for asthma during the 12 months before death. Two age matched control groups were chosen.
investigated further by studying 112 asthma deaths (cases) during 1981-7 in patients aged 5-45 years who had been admitted to a major hospital for asthma during the 12 months before death. Two age matched control groups were chosen.
Control group A comprised 427 patients who had been admitted to hospital for asthma during the calendar year that the corresponding death occurred and who had also had a previous admission for asthma in the previous 12 months. Control group B comprised 448 patients admitted to hospital for asthma during the calendar year in which the admission of the corresponding case occurred. The inhaled fenoterol odds ratio was 2X 11 (95% confidence interval (CI) 1P37-3-23, p < 001) when group A was used as the control (the approach used in previous studies), and 2-66 (95% tI 1-744-06, p < 001) with group B as the control (the approach recommended by critics of previous studies). Markers of chronic asthma severity were associated with asthma death when control group B was used, but not when control group A was used (which indicates that these markers were indirectly matched for when control group A was used). Information was also collected on various markers of acute asthma severity and prescription of psychotropic drugs, but it was found that these were not important confounders. These findings address the major Two recent New Zealand case-control studies,' 2 conducted by our group, evaluated the hypothesis that the unsupervised self administration of fenoterol by inhalation increases the risk of death from asthma. The first national case-control stddy' compared the prescribed drug treatment of patients aged years who died of asthma during August 1981-July 1983 with that of patients with severe asthma who did not die. The findings were consistent with the hypothesis that inhaled fenoterol increases the risk of death in patients with severe asthma. Some possible sources of bias were not excluded, however, particularly as information on prescribed drug treatment for asthma was obtained from different sources for cases and controls. The same hypothesis was evaluated in the second national case-control study,2 which examined asthma deaths during January 1977-July 1981; information on prescribed medication for asthma was obtained from hospital notes for all cases and controls, and the findings were similar to those of the first national study.
We have now conducted a further case-control study of deaths in New Zealanders aged 5-45 years during August 1981-December 1987. The study includes some deaths (August 1981-July 1983) from the first national case-control study,' but uses a different study design and different data sources. The current study uses a design similar to that of the second national case-control study,2 but with several refinements in response to criticisms.34 In particular, a second control group has been added, and further information has been collected on markers of acute and chronic asthma severity and of psychosocial problems, to enable possible sources of bias to be assessed. This paper is primarily orientated to a discussion of methodological issues, rather than being a simple replication of previous studies.
Methods

SELECTION OF CASES
The study was based on 32 hospitals throughout New Zealand. The potential cases comprised all patients aged 5-45 years who died from asthma in New Zealand from August 1981 to December 1987, and who had been admitted to a major hospital for asthma during the 12 months before death. The study was again confined to the 5-45 year age group as death from asthma is a reasonably clearcut diagnosis in this age group.5 Asthma deaths (ICD code 493) were identified from registrations at the National Health Statistics Centre. For each death the records of hospitals to which the patient was likely to have been admitted in an acute attack were then searched to identify any admission for asthma in the previous 12 months. If such an admission was identified the death was included in the study, and the admission closest to death was used as the index admission.
SELECTION OF CONTROLS
Control group A was selected in the same manner as in the second national case-control study.2 Figure 1 illustrates this process (it shows the ideal situation in which the case and [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] (95% CI 0-59-236) with control group A and 3-54 (95% CI 1-82-687) with control group B, and those for oral corticosteroids prescribed at admission were 0-67 (95% CI 0-30-1-48) and 1-25 (95% CI 0-56-2 79) respectively. There was no change in the fenoterol relative risk with group A controls when it was adjusted for an admission in the previous 12 months and prescription of oral corticosteroids at admission; but the relative risk using group B controls fell from 2-66 to 2-34 when this adjustment was made, indicating weak confounding by these markers of chronic severity. Table 5 shows measures of respiratory and metabolic function for the controls, to help assessment of the potential for confounding by severity. ' There was little evidence of systematic differences between the controls prescribed fenoterol and those prescribed other beta agonists. The only exception was in the group A controls, where the mean Paco2 was higher for the index admission (but not for previous admissions) in those prescribed fenoterol (47 v 41 mm Hg (6 3 v 5 5 kPa)). Logistic regression was used to assess potential confounding further. When the risk associated with inhaled fenoterol was adjusted for age, gender, hospital, and date of index admission and for oral theophyllines and oral corticosteroids at discharge the odds ratio based on control group A increased to 2-74, and that based on control group B increased to 2-9 1. In the subgroup ofpatients for whom the Paco2 had been recorded the crude odds ratio based on control group A was 1-48; the estimate increased to 1-87 when the analysis was controlled for the above factors and it fell slightly to 1 71 when Paco2 was added to the model. The corresponding odds ratio estimates with control group B were 2-01, 2-74, and 2 59. These analyses suggest that confounding by these factors was relatively weak, and that the crude odds ratios are likely to be underestimates.
Psychotropic drugs were prescribed at the time of discharge (tranquillisers, neuroleptics, antidepressants, and anticonvulsants) in 1 1 % of cases, 5% of group A controls (odds ratio 2-44, 95% CI 1-18-5-06) and 5% of group B controls (odds ratio 2-44, 95% CI 1 19-5 03). Prescription of these drugs was not, however, associated with prescription of fenoterol in either control group and adjustment for psychotropic drugs made little difference to the odds ratios for inhaled fenoterol: the crude and adjusted odds ratios were 2 1 1 and 2 13 respectively when control group A was used and 2 66 and 2-62 with control group B.
As a final check for possible bias, a further analysis was based only on the prescribed medication at admission (the index admission), with no account taken ofprescribed medication at discharge. With control group A the inhaled fenoterol odds ratio was 2 08 overall, and 2-41, 2-31, 2-31, and 2 24 in the four subgroups of chronic severity defined in table 4. WIhen control group B was used the inhaled fenoterol odds ratio was 2-71 overall and 2-74, 2 31, 2-66, and 3-05 in the four severity subgroups.
Discussion
The increased risk of death from asthma associated with inhalation of fenoterol in the current study is consistent with the previous findings."2 The consistency and magnitude of the findings mean that chance can effectively be ruled out as an explanation for the association between fenoterol and death from asthma. Despite the consistency in overall findings between the various studies, there were some differences in the risk estimates for specific subgroups. In the previous studies'2 the relative risk associated with fenoterol increased substantially when the analysis was restricted to patients with chronic severe asthma, with a roughly 10 fold relative risk in the subgroup with the most severe asthma. In the current study the highest observed relative risks were about fourfold, and the tendency for the relative risk to be greater in the most severely affected subgroups was much weaker. Nevertheless, in terms of assessing the potential for confounding by asthma severity the most important point is that the relative risk associated with fenoterol did not decrease when the analysis was restricted in this manner. Furthermore, the confidence limits of the relative risks in the most severely affected subgroups are relatively wide, and the current findings are consistent with the stronger association seen in the previous studies.
There were also some differences in the findings for specific demographic subgroups between this and previous studies. The second national case-control study2 found a higher relative risk associated with fenoterol in nonEuropeans, whereas the current study found a lower relative risk in non-Europeans. Both previous national studies'2 have found a higher relative risk in patients aged less than 20 years, but this was not observed in the current study. In fact, the demographic differences in relative risk between the various studies are to some extent consistent with the course of the epidemic of fatal asthma, which was particularly severe in younger people and in Maori patients in the early years9 but not subsequently." Maori patients appear to have had a particularly high death rate during the early years of the epidemic9 and a high relative risk associated with inhaling fenoterol,2 but a lower death rate during the latter years of the epidemic" and a lower relative risk. These differences may simply reflect problems of ethnic classification (and the relatively large number of patients for whom ethnic group was not recorded in the current study) or the small numbers of patients in the subgroup analyses (the differences between subgroups in the current study do not reach conventional levels of significance). On the other hand, they might reflect changes in the management of asthma, and in the use of fenoterol, that followed the identification of the epidemic of fatal asthma in 1981.
Increased risk of death from asthma has been associated with some other asthma drugs, such as oral theophyllines and oral corticosteroids in some studies, but not consistently. In particular, oral beta agonists showed an increased relative risk when group B was used as the control in the current study but there was no evidence for this in previous studies.' 2 These inconsistencies in risk estimates for other asthma drugs indicate that some of these findings may have been due to chance, though the possibility that they are due to changes in the form or use of these other asthma medications cannot be excluded.
The main importance of the current study is not in the replication ofprevious findings but in the assessment of possible sources of bias. In particular, two control groups have been used to enable us to address the main methodological criticisms advanced after the previous studies.34
The first methodological criticism related to our previous method of selection of controls.2 The most straightforward approach would have been to select controls from all hospital admissions for asthma (fig 2) . This simple example of a case-control study nested within a cohort study would have been the natural option had there been no concems about confounding within the cohort (study base); a full cohort study would yield the same findings but would be much more expensive and time consuming.'2 To minimise confounding by severity, the additional criterion of an additional admission within 12 months (fig 1) was imposed in the second national case-control study,2 and in control group A in the current study, to ensure that the controls and the cases had asthma of a similar chronic severity.'2 A criticism of this approach was that if prescription of fenoterol led to a decreased rate of hospital admission selection of controls by method A (fig 1) would (table 5) .
A further feature of the current study is that prescription of psychotropic drugs was used to identify patients with potential psychosocial problems, which could affect the management of their asthma. A previous study found that such patients had a relative risk of death from asthma of 3.5,16 and it has been suggested that this might be an important confounder in studies of fenoterol and asthma mortality.20 In the current study prescription of psychotropic drugs was associated with death from asthma (odds ratio = 2 44), but not with prescription of fenoterol, and did not therefore confound the association between fenoterol and asthma death.
In summary, this study has addressed the major criticisms raised in response to previous New Zealand case-control studies of fenoterol and death from asthma. The use of two control groups has indicated that the association between fenoterol and asthma death was not due to the control selection procedure used in previous studies, and that the three major markers of chronic severity (particularly an admission in the previous 12 months) all identify patients at an increased risk of death from asthma. Furthermore, information on various markers of acute asthma severity and on the prescription of psychotropic drugs showed that these factors were not important confounders. Thus the current study addresses the major criticisms of previous studies, and adds support to the hypothesis that the unsupervised self administration of fenoterol by inhalation in patients with severe asthma increases the risk of death.
